Dimerization inhibitors of HIV-1 reverse transcriptase, protease and integrase: A single mode of inhibition for the three HIV enzymes?

Antiviral Research

Volumn 71, Issue 2-3 SPEC. ISS., 2006, Pages 260-267

  Camarasa, María José ^a   Velázquez, Sonsoles ^a   San Félix, Ana ^a   Pérez Pérez, María Jesús ^a   Gago, Federico ^b  

^a INSTITUTO DE QUÍMICA MÉDICA   (Spain)

^b UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

HIV 1; Integrase; Protease; Reverse transcriptase

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DIDEMNAKETAL A; DIDEMNAKETAL B; GUANIDINE DERIVATIVE; HOMODIMER; INTEGRASE; INTEGRASE INHIBITOR; PROTEINASE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; URSOLIC ACID; VIRUS ENZYME;

AMINO TERMINAL SEQUENCE; ANTIVIRAL ACTIVITY; BINDING KINETICS; CARBOXY TERMINAL SEQUENCE; DIMERIZATION; DRUG BINDING SITE; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG SYNTHESIS; ENZYME INHIBITION; ENZYME SUBUNIT; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; NONHUMAN; PEPTIDE SYNTHESIS; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; RETROVIRUS; SHORT SURVEY; VIRUS GENOME; VIRUS INHIBITION; VIRUS REPLICATION;

ANTI-HIV AGENTS; DIMERIZATION; DRUG DESIGN; HIV INTEGRASE; HIV PROTEASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MODELS, MOLECULAR; REVERSE TRANSCRIPTASE INHIBITORS;

HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 33747116051     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2006.05.021     Document Type: Short Survey

References (85)

1. Arion D., Sluis-Cremer N., Min K.L., Abram M.E., Fletcher R.S., and Parniak M.A. Mutational analysis of Tyr-501 of HIV-1 reverse transcriptase. Effects on ribonuclease H activity and inhibition of this activity by N-acylhydrazones. J. Biol. Chem. 277 (2002) 1370-1374
2. Asante-Appiah E., and Skalka A.M. HIV-1 integrase: structural organization, conformational changes, and catalysis. Adv. Virus Res. 52 (1999) 351-369
3. Auwerx J., Rodríguez-Barrios F., Ceccherini-Silberstein F., San Félix A., Velázquez S., De Clercq E., Camarasa M.J., Perno C.F., Gago F., and Balzarini J. Role of T139 in the human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) sensitivity to (+)-calanolide A. Mol. Pharmacol. 68 (2005) 652-659
4. Auwerx J., Van Nieuwenhove J., Rodríguez-Barrios F., de Castro S., Velázquez S., Ceccherini-Silberstein F., De Clercq E., Camarasa M.J., Perno C.F., Gago F., and Balzarini J. The N137 and P140 amino acids in the p51 and the P95 amino acid in the p66 subunit of human immunodeficiency virus type 1 reverse transcriptase (RT) are instrumental to maintain the polymerase activity and are prime targets for the rational design of new classes of anti HIV-1 RT drugs. FEBS Lett. 579 (2005) 2294-2300
5. Babé L.M., Rose J., and Craik C.S. Synthetic "interface" peptides alter dimeric assembly of the HIV 1 and 2 proteases. Protein Sci. 1 (1992) 1244-1253
6. Baillon J.G., Nashed N.T., Kumar A., Wilson S.H., and Jerina D.M. A leucine zipper-like motif may mediate HIV reverse transcriptase subunit binding. New Biol. 3 (1991) 1015-1019
7. Balzarini J., Pérez-Pérez M.J., San-Félix A., Schols D., Perno C.F., Vandamme A.M., Camarasa M.J., and De Clercq E. 2′,5′-Bis-O-(tert-butyldimethylsilyl)-3′-spiro-5″-(4″-amino-1″,2″-oxathiole-2″,2-dioxide)pyrimidine (TSAO) nucleoside analogues: highly selective inhibitors of human immunodeficiency virus type 1 that are targeted at the viral reverse transcriptase. Proc. Natl. Acad. Sci. U.S.A. 89 (1992) 4392-4396
8. Balzarini J., Auwerx J., Rodríguez-Barrios F., Chedad A., Farkas V., Ceccherini-Silberstein F., García-Aparicio C., Velázquez S., De Clercq E., Perno C.F., Camarasa M.J., and Gago F. The amino acid N136 in HIV-1 reverse transcriptase (RT) maintains efficient association of both Rtsubunits and enables the rational design of novel RT inhibitors. Mol. Pharmacol. 68 (2005) 49-60
9. Basu A., Basu S., and Modak M.J. Structure-activity analyses of HIV-1 reverse transcriptase. Biochem. Biophys. Res. Commun. 183 (1992) 1131-1138
10. Becerra S.P., Kumar A., Lewis M.S., Widen S.G., Abbotts J., Karawya E.M., Hughes S.H., Shiloach J., and Wilson S.H. Protein-protein interactions of HIV-1 reverse transcriptase: implications of central and C-terminal regions in subunit binding. Biochemistry 30 (1991) 11707-11719
11. Bonache M.C., Chamorro C., Velázquez S., De Clercq E., Balzarini J., Rodríguez-Barrios F., Gago F., Camarasa M.J., and San-Félix A. Improving the antiviral efficacy and selectivity of HIV-1 reverse transcriptase inhibitor TSAO-T by the introduction of functional groups at the N-3 position. J. Med. Chem. 48 (2005) 6653-6660
12. Borkow G., Fletcher R.S., Barnard J., Arion D., Motakis D., Dmitrienko G.I., and Parniak M.A. Inhibition of the ribonuclease H and DNA polymerase activities of HIV-1 reverse transcriptase by N-(4-tert-butylbenzoyl)-2-hydroxy-1-naphthaldehyde hydrazone. Biochemistry 36 (1997) 3179-3185
13. Bouras A., Boggetto N., Benatalah Z., de Rosny E., Sicsic S., and Reboud-Rovaux M. Design, synthesis and evaluation of conformationally constrained tongs, new inhibitors of HIV-1 protease dimerization. J. Med. Chem. 42 (1999) 957-962
14. Boyer P.L., Ding J., Arnold E., and Hughes S.H. Subunit specificity of mutations that confer resistance to nonnucleoside inhibitors in human immunodeficiency virus type 1 reverse transcriptase. Antimicrob. Agents Chemother. 38 (1994) 1909-1914
15. Breccia P., Boggetto N., Pérez-Frenández R., Van Gool M., Takahashi M., René L., Prados P., Badet B., Rebond-Ravaux M., and De Mendoza J. Dimerization inhibitors of HIV-1 protease based on a bicyclic guanidinium subunit. J. Med. Chem. 46 (2003) 5196-5207
16. Cai M., Zheng R., Caffrey M., Craigee R., Clore G.M., and Gronenborn A.M. Solution structure of the N-terminal zinc binding domain of HIV-1 integrase. Nat. Struct. Biol. 4 (1997) 567-577 (Erratum in Nat. Struct. Biol. 4 (1997) 839-840)
17. Camarasa M.J., Pérez-Pérez M.J., San-Félix A., Balzarini J., and De Clercq E. 3′-Spironucleosides a new class of specific human immunodeficiency virus type 1 inhibitors: synthesis and antiviral activity of [2′,5′-bis-O-(tert-butyldimethylsilyl)-β-d-xylo and ribofuranose]-3′-spiro-5″-[4″-amino-1″,2″-oxathiole-2″,2″-dioxide] (TSAO) pyrimidine nucleosides. J. Med. Chem. 35 (1992) 2721-2727
18. Camarasa M.J., San-Félix A., Velázquez S., Pérez-Pérez M.J., Gago F., and Balzarini J. TSAO compounds: the comprehensive story of a unique family of HIV-1 specific inhibitors of reverse transcriptase. Curr. Top. Med. Chem. 4 (2004) 945-963
19. de Castro S., Lobatón E., Pérez-Pérez M.J., San-Félix A., Cordeiro A., Andrei G., Snoeck R., De Clercq E., Balzarini J., Camarasa M.J., and Velázquez S. Novel [2′,5′-bis-O-(tert-butyldimethylsilyl)-β-d-ribofuranosyl]-3′-spiro-5″-(4″-amino-1″,2″-oxathiole-2″,2″-dioxide) derivatives with anti-HIV-1 and anti-human-cytomegalovirus activity. J. Med. Chem. 48 (2005) 1158-1168
20. Chen J.C., Krucinskji J., Miercke L.J., Finer-Moore J.S., Tang A.H., Leavitt A.D., and Stroud R.M. Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: a model for viral DNA binding. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 8233-8238
21. Chiu T.K., and Davies D.R. Structure and function of HIV-1 integrase. Curr. Top. Med. Chem. 4 (2004) 965-979
22. Depollier J., Hourdou M.L., Aldrian-Herrada G., Rothwell P., Restle T., and Divita G. Insight into the mechanism of a peptide inhibitor of HIV reverse transcriptase dimerization. Biochemistry 44 (2005) 1909-1918
23. Divita G., Restle T., and Goody R.S. Characterization of the dimerization process of HIV-1 reverse transcriptase heterodimer using intrinsic protein fluorescence. FEBS Lett. 324 (1993) 153-158
24. Divita G., Restle T., Goody R.S., Chermann J.C., and Baillon J.G. Inhibition of human immunodeficiency virus type 1 reverse transcriptase dimerization using synthetic peptides derived from the connection domain. J. Biol. Chem. 269 (1994) 13080-13083
25. Divita G., Rittinger K., Geourjon C., Deleage G., and Goody R.S. Dimerization kinetics of HIV-1 and HIV-2 reverse transcriptase: a two step process. J. Mol. Biol. 245 (1995) 508-521
26. Engelman A., Bushman F.D., and Craige R. Identification of discrete function domains of HIV-1 integrase and their organization within an active multimeric complex. EMBO J. 12 (1993) 3269-3275
27. Engelman A., and Craigie R. Identification of conserved amino-acid-residues critical for human-immunodeficiency-virus type-1 integrase function-in vitro. J. Virol. 66 (1992) 6361-6369
28. Esposito D., and Craigie R. HIV integrase structure and function. Adv. Virus Res. 52 (1999) 319-333
29. Fan X., Flentke G.R., and Rich D.H. Inhibition of HIV-1 protease by a subunit of didemnaketal A. J. Am. Chem. Soc. 120 (1998) 8893-8894
30. Frankel A.D., and Young J.A.T. HIV-1: fifteen proteins and an RNA. Annu. Rev. Biochem. 67 (1998) 1-25
31. Gago F. Targeting HIV-1 protease: from peptidomimetics to non-peptide inhibitors. IDrugs 2 (1999) 309-320
32. Goel R., Beard W.A., Kumar A., Casas-Finet J.R., Strub M.P., Stahl S.J., Lewis M.S., Bebenek K., Becerra S.P., Kunkel T.A., and Wilson S.H. Structure/function studies of HIV-1 reverse transcriptase: dimerization-defective mutant L289K. Biochemistry 32 (1993) 13012-13018
33. Harris D., Lee R., Misra H.S., Pandey P.K., and Pandey V.N. The p51 subunit of human immunodeficiency virus type 1 reverse transcriptase is essential in loading the p66 subunit on the template primer. Biochemistry 37 (1998) 5903-5908
34. Huff J.R. HIV protease: a novel chemotherapeutic target for AIDS. J. Med. Chem. 34 (1991) 2305-2314
35. Huang H., Chopra R., Verdine G.L., and Harrison S.C. Structure of a covalently trapped catalytic complex of HIV-1 reverse transcriptase: implications for drug resistance. Science 282 (1998) 1669-1675
36. Hwang Y.S., and Chmielewski J. A unidirectional crosslinking strategy for HIV-1 protease dimerization inhibitors. Bioorg. Med. Chem. Lett. 14 (2004) 4297-4300
37. Jonckheere H., Taymans J.M., Balzarini J., Velázquez S., Camarasa M.J., Desmyter J., De Clercq E., and Anne J. Resistance of HIV-1 reverse transcriptase against [2′,5′-bis-O-(tert-butyldimethylsilyl)-3′-spiro-5″-(4″-amino-1″,2″-oxathiole-2″,2″-dioxide)] (TSAO) derivatives is determined by the mutation Glu138 → Lys on the p51 subunit. J. Biol. Chem. 269 (1994) 25255-25258
38. Jordan M.A. Mechanism of action of antitumor drugs that interact with microtubules and tubulin. Curr. Med. Chem. Anti-Cancer Agents 2 (2002) 1-17
39. Katzman M., and Sudol M. Mapping domains of retroviral integrase responsible for viral-DNA specificity and target site selection by analysis of chimeras between human-immunodeficiency-virus type-1 and visna virus integrases. J. Virol. 69 (1995) 5687-5696
40. Keskin O., Ma B.Y., and Nussinov R. Hot regions in protein-protein interactions: the organization and contribution of structurally conserved hot spot residues. J. Mol. Biol. 345 (2005) 1281-1294
41. Kohlstaedt L.A., Wang J., Fiedman J.M., Rice P.A., and Steitz T.A. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 256 (1992) 1783-1790
42. Krajewski K., Marchand C., Long Y.Q., Pommier Y., and Roller P.P. Synthesis and HIV-1 integrase inhibitory activity of dimeric and tetrameric analogs of indolicidin. Bioorg. Med. Chem. Lett. 14 (2004) 5595-5598
43. Krajewski K., Long Y.Q., Marchand C., Pommier Y., and Roller P.P. Design and synthesis of dimeric HIV-1 integrase inhibitory peptides. Bioorg. Med. Chem. Lett. 13 (2003) 3203-3205
44. Lebon F., and LeClecq M. Approaches to the design of effective HIV-1 protease inhibitors. Curr. Med. Chem. 7 (2000) 455-477
45. Lobatón E., Rodríguez-Barrios F., Gago F., Pérez-Pérez M.J., De Clercq E., Balzarini J., Camarasa M.J., and Velázquez S. Synthesis of 3″-substituted TSAO derivatives with anti-HIV-1 and anti-HIV-2 activity through an efficient palladium-catalyzed cross-coupling approach. J. Med. Chem. 45 (2002) 3934-3945
46. Loregian A., Marsden H.S., and Palù G. Protein-protein interactions as targets for antiviral chemotherapy. Rev. Med. Virol. 12 (2002) 239-262
47. Loregian A., and Palù G. Disruption of protein-protein interactions: towards new targets for chemotherapy. J. Cell. Physiol. 204 (2005) 750-762
48. Lutzke R.A., and Plasterk R.A. Structure-based mutational analysis of the C-terminal DNA-binding domain of human immunodeficiency virus type 1 integrase: critical residues for protein oligomerization and DNA binding. J. Virol. 72 (1998) 4841-4848
49. Lutzke R.A.P., Eppens N.E., Weber P.A., Houghten R.A., and Plasterk R.H.A. Identification of a hexapaptide inhibitor of the human immunodeficiency virus integrase protein by using a combinatorial library. Proc. Natl. Acad. Sci. U.S.A. 92 (1995) 11456-11460
50. Maroun R.G., Gayet S., Benleulmi M.S., Porumb H., Zargarian L., Merad H., Leh H., Mouscadet J.F., Troalen F., and Fermandjian S. Peptide inhibitors of HIV-1 integrase dissociate the enzyme oligomers. Biochemistry 40 (2001) 13840-13848
51. Merabet N., Dumond J., Collinet B., Van Baelinghem L., Bogetto N., Ongeri S., Ressad F., Rebond-Ravaux M., and Sicisc S. New constrained "nuclear tongs" designed to dissociate HIV-1 protease dimer. J. Med. Chem. 47 (2004) 6392-6400
52. Morris M.C., Robert-Hebmann V., Chaloin V.L., Mery J., Heitz F., Devaux C., Goody R.S., and Divita G. A new potent HIV-1 reverse transcriptase inhibitor. J. Biol. Chem. 274 (1999) 24941-24946
53. Müller B., Restle T., Weiss S., Gautel M., Sczakiel G., and Goody R.S. Co-expression of the subunits of the heterodimer of HIV-1 reverse transcriptase in Escherichia coli. J. Biol. Chem. 264 (1989) 13975-13978
54. Nicholson L.K., Yamazaki T., Torchia D.A., Grzesiek S., Bax A., Stahl S.J., Kaufman J.D., Wingfield P.T., Lam P.Y., Jadhav P.K., Hodge C.N., Domaille P.J., and Chang C.-H. Flexibility and function in HIV-1 protease. Nat. Struct. Biol. 2 (1995) 274-280
55. Ockey D.A., and Gadek T.R. Inhibitors of protein-protein interactions. Expert Opin. Ther. Pat. 12 (2002) 393-400
56. Oroszlan S., and Luftig R.B. Retroviral proteinases. Curr. Top. Microbiol. Immunol. 157 (1990) 153-185
57. Pandey P.K., Kaushik N., Talele T.T., Yadav P.N.S., and Pandey V.N. The β7-β8 loop of the p51 subunit in the heterodimeric (p66/p51) human immunodeficincy virus type 1 reverse transcriptase is essential for the catalytic function of the p66 subunit. Biochemistry 40 (2001) 9505-9512
58. Pandey P.K., Kaushik N., Singh K., Sharma B., Upadhyay A.K., Kumar S., Harris D., and Pandey V.N. Insertion of a small peptide of six amino acids into the β7-β8 loop of the p51 subunit of HIV-1 reverse transcriptase perturbs the heterodimer and affects its activities. BMC Biochem. 3 (2002) 18-31
59. Park S.H., and Raines R.T. Genetic selection for dissociative inhibitors of designated protein-protein interactions. Nat. Biotechnol. 18 (2000) 847-851
60. Pommier Y., and Cherfils J. Intefacial inhibition of macromolecular interactions: nature's paradigm for drug discovery. Trends Pharmacol. Sci. 26 (2005) 138-145
61. Priestle J.P., Fassler A., Rosel J., Tintelnot-Blomley M., Strop P., and Grutter M.G. Comparative analysis of the X-ray structures of HIV-1 and HIV-2 proteases in complex with CGP 53820, a novel pseudosymmetric inhibitor. Structure 3 (1995) 381-389
62. Restle T., Müller B., and Goody R.S. Dimerization of human immunodeficiency virus type 1 reverse transcriptase. A target for chemotherapeutic intervention. J. Biol. Chem. 265 (1990) 8986-8988
63. Restle T., Müller B., and Goody R.S. RNase H activity of HIV reverse transcriptases is confined exclusively to the dimeric forms. FEBS Lett. 300 (1992) 97-100
64. Robinson Jr. W.E., McDougall B., Tran D., and Selsted M.E. Anti-HIV-1 activity of indolicidin, an antimicrobial peptide from neutrophils. Leukoc. Biol. 63 (1998) 94-100
65. Rodríguez-Barrios F., Pérez C., Lobatón E., Velázquez S., Chamorro C., San-Félix A., Pérez-Pérez M.J., Camarasa M.J., Pelemans H., Balzarini J., and Gago F. Identification of a putative binding site for [2′,5′-bis-O-(tert-butyldimethylsilyl)-β-d-ribofuranosyl]-3′-spiro-5″-(4″-amino-1″,2″-oxathiole-2″,2″-dioxide)thymine (TSAO) derivatives at the p51-p66 interface of HIV-1 reverse transcriptase. J. Med. Chem. 44 (2001) 1853-1865
66. Schramm H.J., Billich A., Jaeger E., Wakayama H., Rucknagel K.-P., Arnold G., and Schramm W. The inhibition of HIV-1 protease by interface peptides. Biochem. Biophys. Res. Commun. 194 (1993) 595-600
67. Schramm H.J., Boetzel J., Buttner J., Fritsche E., Gohring W., Jaeger E., Konig S., Thumfart O., Wenger T., Nagel N.E., and Schramm W. The inhibition of human immunodeficiency virus proteases by "interface peptides". Antiviral Res. 30 (1996) 155-170
68. Schramm H.J., Nakashima H., Schramm W., Wakayama H., and Yamamoto N. HIV-1 reproduction is inhibited by peptides derived from the N- and C-termini of HIV-1 protease. Biochem. Biophys. Res. Commun. 179 (1991) 847-851
69. Sluis-Cremer N., Arion D., and Parniak M.A. Destabilization of the HIV-1 reverse transcriptase dimer upon interaction with N-acyl hydrazone inhibitors. Mol. Pharmacol. 62 (2002) 398-405
70. Sluis-Cremer N., Dmitrienko G.I., Balzarini J., Camarasa M.J., and Parniak M.A. Human immunodeficiency virus type 1 reverse transcriptase dimer destabilization by 1-[spiro[4″-amino-2″,2″-dioxo-1″,2″-oxathiole-5″,3′-[2′,5′-bis-O-(tert-butyldimethylsilyl)-β-d-ribofuranosyl]]]-3-ethylthymine. Biochemistry 39 (2000) 1427-1433
71. Sluis-Cremer N., and Tachedjian G. Modulation of the oligomeric structures of HIV-1 retroviral enzymes by synthetic peptides and small molecules. Eur. J. Biochem. 269 (2002) 5103-5111
72. Smith R., Brereton I.M., Chai R.Y., and Kent S.B. Ionization states of the catalytic residues in HIV-1 protease. Nat. Struct. Biol. 3 (1996) 946-950
73. Song M.-C., Rajesh S., Hayashi Y., and Kiso Y. Design and synthesis of new inhibitors of HIV-1 protease dimerization with conformationally constrained templates. Bioorg. Med. Chem. Lett. 11 (2001) 2465-2468
74. Sourgen F., Maroun R.G., Frere V.M., Bouziane R.G., Auclair C., Troalen F., and Fermandjian S. A synthetic peptide from the human immunodeficiency virus type-1 integrase exhibits coiled-coil properties and interferes with the in vitro integration activity of the enzyme. Eur. J. Biochem. 240 (1996) 765-773
75. Tachedjian G., and Goff S.P. The effect of NNRTIs on HIV reverse transcriptase dimerization. Curr. Opin. Investig. Drugs 4 (2003) 966-973
76. Tachedjian G., Orlova M., Sarafianos S.G., Arnold E., and Goff S.P. Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase. Proc. Natl. Acad. Sci. U.S.A. 98 (2001) 7188-7193
77. Tomasselli A.G., and Heinrikson R.L. Targeting the HIV-protease in AIDS therapy: a current clinical perspective. Biochim. Biophys. Acta 1477 (2000) 189-214
78. Toogood P.L. Inhibition of protein-protein association by small molecules. Approaches and progress. J. Med. Chem. 45 (2002) 1543-1558
79. Wang J.Y., Ling H., Yang W., and Craigie R. Structure of a two-domain fragment of HIV-1 integrase: implications for domain organization in the intact protein. EMBO J. 20 (2001) 7333-7343
80. Wlodawer A., Miller A., Jaskolski M., Sathyanarayana B., Baldwin E., Weber I., Selk L., Clawson L., Schneider J., and Kent S. Conserved folding in retroviral proteases: crystal structure of a synthetic HIV-1 protease. Science 245 (1989) 616-621
81. Wlodawer A., and Erickson J.W. Structure-based inhibitors of HIV-1 protease. Annu. Rev. Biochem. 62 (1993) 543-585
82. Zhang Z., Poorman R., Maggiora L., Heinrikson R., and Kezdy F. Dissociative inhibition of dimeric enzymes. Kinetic characterization of the inhibition of HIV-1 protease by its COOH-terminal tetrapeptide. J. Biol. Chem. 266 (1991) 15591-15594
83. Zhao L., O'Reilly M.K., Shultz M.D., and Chmielewski J. Interfacial peptide inhibitors of HIV-1 integrase activity and dimerization. Bioorg. Med. Chem. Lett. 13 (2003) 1175-1177
84. Zutshi C.R., and Chmielewski J. Targeting the dimerization interface for irreversible inhibition of HIV-1 protease. Bioorg. Med. Chem. Lett. 10 (2000) 1901-1903
85. Zutshi R., Franciskovich J., Shultz M., Schweitzer B., Bishop P., Wilson M., and Chmielewski J. Targeting the dimerization interface of HIV-1 protease: inhibition with cross-linked interfacial peptides. J. Am. Chem. Soc. 119 (1997) 4841-4845